SCHEMBL3474153

SCHEMBL3474153

CS(=O)(=O)c1cccc(-c2ccc(-c3cc(C(=O)N4CCC[C@H]4CO)nn3-c3ccccc3Cl)s2)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 7/20 0.65
NR1H2 P55055 7/20 0.65
NR1H3 Q13133 7/20 0.65
NTRK1 P04629 2/20 0.37
SCD5 Q86SK9 1/20 0.37
ABL1 P00519 1/20 0.36
RIN1 Q13671 1/20 0.36
CNR1 P21554 1/20 0.35
NPC1 O15118 1/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35
SLC16A3 O15427 3/20 0.35
SLC16A1 P53985 3/20 0.35
MCTS1 Q9ULC4 1/20 0.35
CPT2 P23786 1/20 0.35
CPT1A P50416 1/20 0.35
HCRTR1 O43613 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3472730 0.92 RXRA (0.62) RXRANR1H2NR1H3NTRK1ABL1
SCHEMBL15641672 0.87 RXRA (0.63) RXRANR1H2NR1H3NPC1LMNA
SCHEMBL3474279 0.87 RXRA (0.65) RXRANR1H2NR1H3CNR1LMNA
SCHEMBL3471296 0.85 RXRA (0.74) RXRANR1H2NR1H3CNR1NPC1
SCHEMBL3474653 0.84 NR1H2 (0.62) RXRANR1H2NR1H3NPC1HPGD
SCHEMBL3472436 0.84 RXRA (0.73) RXRANR1H2NR1H3CNR1NPC1
SCHEMBL3472067 0.84 RXRA (0.66) RXRANR1H2NR1H3CNR1NPC1
SCHEMBL3471280 0.84 RXRA (0.60) RXRANR1H2NR1H3LMNASLC16A3
SCHEMBL3473318 0.84 RXRA (0.72) RXRANR1H2NR1H3CNR1LMNA
SCHEMBL3474509 0.84 RXRA (0.70) RXRANR1H2NR1H3CNR1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US claimed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-8703805-B2 Modulators of LXR EXELIXIS PATENT COMPANY LLC (US) 2014-04-22 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed
US-20100331295-A1 MODULATORS OF LXR EXELIXIS, INC. (US) 2010-12-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331295-A1 MODULATORS OF LXR NR1H2, NR1H3, NR1H4 RXRA 18/4885NR1H2 1/4885NR1H3 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.